Scope and limitations of antimicrobial therapy of sepsis in surgery

Langenbeck's Archives of Surgery

Volumn 383, Issue 1, 1998, Pages 15-25

  Wittmann, D H ^a   Wittmann Tylor, A ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Antibiotics; Controlled clinical trial; Defense failure syndrome; Infected pancreatic necrosis; Intra abdominal infection; Pharmacodynamics; Sepsis; Systemic inflammatory response syndrome

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CIPROFLOXACIN; IMIPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE;

ABDOMINAL INFECTION; ANTIMICROBIAL THERAPY; CLINICAL TRIAL; DRUG CHOICE; GRAM NEGATIVE INFECTION; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; REVIEW; SEPSIS; SURGICAL INFECTION;

ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CEPHALOSPORINS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROBIAL SENSITIVITY TESTS; PANCREATITIS, ACUTE NECROTIZING; PERITONITIS; SHOCK, SEPTIC; SURGICAL WOUND INFECTION; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0031970187     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004230050087     Document Type: Review

References (96)

1. Aasen AO (1990) Surgical pathophysiology. Chur, pp 1-452
2. Akaniro, JC, Vidaurre, CE, Stutman, HR, Marks, MI (1990) Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother 34:1880-1884
3. Andaker L, Burman LG, Eklund A, Graffner H, Hansson J, Hellberg R. Hoejer H, Ljungqvist U, Kjellgren K, Kling PA, Krook H, Lindhagen J, Molin K (1992) Fosfomycin/metronidazole compared with doxycycline/metronidazole for the prophylaxis of infection after elective colorectal surgery. Eur J Surg 158:181-185
4. Androulakis J, Diamantis T, Stavropoulos M (1988) The present status of efficacy of the combination of cefotaxime-metronidazole in the treatment of peritonitis. Int J Exp Clin Chemother 12:51-54
5. Anonymous (1990) Increase in National Hospital Discharge Survey rates for septicemia -United States, 1979-1987. MMWR Morbid Mortal Wkly Rep 39:31-34
6. Arguedas AG, Akaniro JC, Stutman HR, Marks MI (1990) In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum. Antimicrob Agents Chemother 34:2223-2227
7. Barriere SL, Lowry SF (1995) An overview of mortality risk prediction in sepsis. Crit Care Med 23:376-393
8. Barry AL, Fuchs PC (1991) In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother 35:955-960
9. Beskid G, Fallat V, Lipschitz ER, McGarry DH, Cleeland R, Chan K, Keith DD, Unowsky J (1989) In vitro activities of a dual-action antibacterial agent. Ro 23-9424, comparative agents. Antimicrob Agents Chemother 33:1072-1077
10. Biron S, Brochu G, Gourque RA (1984) Short-term antibiotherapy for peritonitis: prospective, randomized trial comparing cefotaxime-metronidazole and clindamycin-tobramycin. J Antimicrob Chemother 14 [Suppl]:S213-S216
11. Bone RC (1991) Let's agree on terminology: definitions of sepsis. Crit Care Med 19:973-976
12. Bone RC (1992) Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 268:3452-3455
13. Bone RC (1995) Sepsis. SIRS and MODS the new definition. Proceedings of sepsis/SIRS. Washington
14. Cerra FB (1987) Hypermetabolism, organ failure, and metabolic support. Surgery 101:1-14
15. Chin NX, Gu JW, Yu KW, Zhang YX, Neu HC (1991) In vitro activity of sparfloxacin. Antimicrob Agents Chemother 35:567-571
16. Chow AW, Wong J, Bartlett KH (1988) Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia. Antimicrob Agents Chemother 32:782-784
17. Clark RB, Sanders CC, Pakiz CB, Hostetter MK (1988) Aminoglycoside resistance among Pseudomonas aeruginosa isolates with an unusual disk diffusion antibiogram. Antimicrob Agents Chemother 32:689-692
18. Coleman K, Griffin DR, Page JW, Upshon PA (1989) In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor. Antimicrob Agents Chemother 33:1580-1587
19. Condon RE, Wittmann DH (1991) The use of antibiotics in general surgery. Curr Prob Surg 28:801-949
20. Condon RE, Wittmann DH (1994) Surgical infection. In: Morris PJ (ed) Oxford textbook of surgery. Oxfore, Oxford University Press, pp 27-44
21. Condon RE, Walker AP, Sirinek KR, White PW, Fabian TCXNR, Wilson SE (1995) Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 21:544-550
22. Craig WA, Ebert SC (1991) Killing and regrowth of bacteria in vivo. A review. Scand J Infect Dis 74 [Suppl]:63-70
23. Craig WA, Ebert SC (1992) Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 36:2577-2583
24. Craig WA, Vogelman B (1984) Changing concepts and new applications of antibiotic pharmacokinetics. Am J Med July:24-28
25. Cuchural GJ, Tally FP, Jacobus NV, Aldridge K, Cleary T, Finegold SM, Hill G, Iannini P, O'Keefe JP, Pierson C, Crook D, Russo T, Hecht D (1988) Susceptibility of the bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother 32:717-722
26. Cuchural GJJ, Tally FP, Jacobus NV, Aldridge K, Cleary T, Finegold SM. Hill G, Iannini P, O'Keefe JP, Pierson C (1988) Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother 32:717-722
27. Cuchural GJJ, Tally FP, Jacobus NV, Cleary T, Finegold SM, Hill G, Iannini P, O'Keefe JP, Pierson C (1990) Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group. Antimicrob Agents Chemother 34:479-480
28. De Privitera LFG, Rinaldi E, Ortisi G, Santoro D, Rizzardini G (1989) Treatment of Clostridium difficile-associated disease with teicoplanin. Antimicrob Agents Chemother 33:1125-1127
29. Drusano GL, Craig WA (1997) Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 9 [Suppl 3]:38-44
30. Edwards JR, Turner PJ, Wannop C, Withnell ES, Grindey AJ, Nairn K (1989) In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother 33:215-222
31. Eklund AE, Nord CE (1993) A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. J Antimicrob Chemother 31 [Suppl A]:79-85
32. Eliopoulos GM, Klimm K, Rice LB, Ferraro MJ, Moellering RC Jr (1990) Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob Agents Chemother 34:1154-1159
33. Erwin ME, Jones RN, Barrett MS, Briggs BM, Johnson DM (1991) In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin. Antimicrob Agents Chemother 35:929-937
34. Espinoza AM, Chin NX, Novelli A, Neu HC (1988) Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother 32:663-670
35. Fuchs PC, Barry AL, Pfaller MA, Allen SD, Gerlach EH (1991) Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother 35:764-766
36. Fung-Tomc J, Huczko E, Kolek B, Thater C, Kessler RE (1991) In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria. Antimicrob Agents Chemother 35:2652-2654
37. Gargallo-Viola D, Esteve M, Moros M, Coll R, Xicota MA, De AC, Roser R, Guinea J (1990) Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent. Antimicrob Agents Chemother 34:2318-2326
38. Gootz T, Retsema J, Girard A, Hamanaka E, Anderson M, Sokolowski S (1989) In vitro activity of CP-65,207. a new penem antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother 33:1160-1166
39. Goris RJA, te Boekhorst TPA, Nuytinck HKS, Gimbrere JSF (1985) Multiple-organ failure. generalized autodestructive inflammation? Arch Surg 120:1109-1115
40. Goris RJA, Boekholz WKF, Van Bebber IPT, Nuytinck HKS, Schillings PHM (1986) Multiple-organ failure and sepsis without bacteria. An experimental model. Arch Surg 121:897-900
41. Gu JW, Neu HC (1990) In vitro activity of Ro 23-9424, a dualaction cephalosporin, compared with activities of other antibiotics. Antimicrob Agents Chemother 34:189-195
42. Jones RN, Aldndge KE, Allen SD, Barry AL, Fuchs P C, Gerlach EH, Pfaller MA (1989) Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrob Agents Chemother 33:562-565
43. Jones RN, Aldridge KE, Allen SD, Barry AL, Fuchs PC, Gerlach EH, Pfaller MA (1989) Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrob Agents Chemother 33:562-565
44. Jones RN, Barry AL, Thornsberry C (1989) Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime. Antimicrob Agents Chemother 33:944-950
45. Jonsson B, Berglund J, Skau T, Nystrom PO (1993) Outcome of intra-abdominal infection in pigs depends more on host responses than on microbiology. Eur Surg 159:571-578
46. Kaatz GW, Seo SM (1990) WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens. Antimicrob Agents Chemother 34:1376-1380
47. Kirby WMM, Craig WA (1981) Theory and applications of pulse dosing: a summary of the symposium. Rev Infect Dis 3:1-3
48. Krepel CJ, Gohr CM, Edmiston CE, Condon RE (1995) Surgical sepsis: constancy of antibiotic susceptibility of causative organisms. Surgery 117:505-509
49. Limbert M, Isert D, Klesel N, Markus A, Seeger K, Seibert G, Schrinner (1991) Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 35:14-19
50. Maejima T, Inoue M, Mitsuhashi S (1991) In vitro antibacterial activity of KP-736, a new cephem antibiotic. Antimicrob Agents Chemother 35:104-110
51. Marshall JC, Sweeney D (1990) Microbial Infection and the spetic response in critical illness: sepsis, not infection, determines outcome. Arch Surg 125:17-23
52. Meakins JL, Wicklund B, Forse RA, McLean APH (1980) The surgical intensive care unit: current concepts in infection. Surg Clin North Am 60:117-132
53. Nakagawa S, Sanada M, Matsuda K, Hashizume T, Asahi Y, Ushijima R, Ohtake N, Tanaka N (1989) In vitro and in vivo antibacterial activities of BO-1341, a new antipseudomonal cephalosporin. Antimicrob Agents Chemother 33:1423-1427
54. Neu HC, Novelli A, Chin NX (1989) Comparative in vitro activity of a new quinolone, AM-1091. Antimicrob Agents Chemother 33:1036-1041
55. Neu HC, Novelli A, Chin NX (1989) In vitro activity and betalactamase stability of a new carbapenem. SM-7338. Antimicrob Agents Chemother 33.1009-1018
56. Neu HC, Saha G, Chin NX (1989) In vitro activity of ME1228, a new parenteral cephalosporin. Antimicrob Agents Chemother 33:1260-1267
57. Nord CE, Lindmark A, Persson I (1989) Susceptibility of anaerobic bacteria to ALP 201. Antimicrob Agents Chemother 33:2137-2139
58. Nystrom PO (1996) Transition from contamination to infection: implications in colonic surgery. Eur J Surg 162 [Suppl 576]:42-46
59. O'Brien PE, Tait N, Bushell M (1987) Management of diffuse peritonitis by prolonged postoperative peritoneal lavage. Aust NZ J Surg 57:181-184
60. Petersen PJ, Jacobus NV, Weiss WJ, Testa RT (1991) In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I. Antimicrob Agents Chemother 35:203-207
61. Polk HC Jr, Fink MP, Laverdiere M, Wilson SE, Garber GE, Barie PS, Hebert JC, Cheadle WG (1993) Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. Am Surg 59:598-605
62. Quartin AA, Schein RM, Kett DH, Peduzzi PN (1997) Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 277:1058-1063
63. Rolston KVI, Nguyen H, Messer M, LeBlanc B, Ho DH, Bodey GP (1990) In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. Antimicrob Agents Chemother 34:2263-2266
64. Schein M (1991) Severe intra-abdominal infection today. S Afr Med J 80:417-418
65. Schein M, Wittmann DH, Lorenz W (1996) Discussion forum on antibiotic treatment of post-operative abdominal infections. Eur J Surg 162 [Suppl 576]:1-75
66. Schottmüller H (1914) Wesen und Behandlung der Sepsis. Verhandl Dtsch Kongr Inn Med 31:17-280
67. Sedlock DM, Dobson RA, Deuel DM, Lesher GY, Rake JB (1990) In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother 34:568-575
68. Sentochnik DE, Eliopoulos GM, Ferraro MJ, Moellering RC Jr (1989) Comparative in vitro activity of SM7338, a new carbapenem antimicrobial agent. Antimicrob Agents Chemother 33:1232-1236
69. Smith RP, Baltch AL, Hammer MC, Conroy JV (1988) In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains. Antimicrob Agents Chemother 32:1450-1455
70. Solomkin JS (1996) Duration of antibiotic treatment in surgical infections of the abdomen. The future: randomised prospective studies. Eur Surg 162 [Suppl]:33-35
71. Solomkin JS, Meakins JL, Dellinger EP, Meakins JL Jr, Allo MD, Simmons RL (1984) Antibiotics trials in intra-abdominal infections: a critical evaluation of study design and outcome reporting. Ann Surg 200:29-39
72. Solomkin JS, Reinhart HH, Dellinger EP, Bohnen JM, Rotstein OD, Vogel SB, Simms HH, Hill CS, Bjornson HS, Haverstock DC, Coulter HO, Echols RM (1996) Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 223:303-315
73. Strom PR, Fabian TC, Dunlop WE, Stone HH (1983) The third generation cephalosporins in polymicrobial surgical infections. Arch Surg 118:193-200
74. Stutman HR, Akaniro JC, Vidaurre CE, Marks MI (1990) In vitro activity of E-1040, a 3-substituted cephalosporin, against pathogens from cystic fibrosis sputum. Antimicrob Agents Chemother 34:1366-1370
75. Venditti M, Baiocchi P, Santini C, Brandimarte C, Serra P, Gentile G, Girmenia C, Martino P (1989) Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients. Antimicrob Agents Chemother 33:580-582
76. Venezia RA, Prymas LA, Shayegani A, Yocum DM (1989) In vitro activities of amifloxacin and two of its metabolites. Antimicrob Agents Chemother 33:762-766
77. Venezia RA, Yocum DM, Robbiano EM, Echols RM (1990) Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria. Antimicrob Agents Chemother 34:1858-1861
78. Vestweber KH, Borisch N, Jorstarndt L, Ullmann U (1983) Single shot antibiotic prophylaxis with mezlocillin versus a long term regimen in colonic surgery. In: Spitzy KH, Pichler H (eds) Proceedings of the 13th International Congress of Chemotherapy. Vienna
79. Vincent JL, Bihari DJ, Suter PM, Bruinine HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 274:639-644
80. Visser MR, Rozenberg-Arska M, Beumer H, Hoepelman IM, Verhoef J (1991) Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Antimicrob Agents Chemother 35:858-868
81. Visser MR, Rozenberg-Arska M, Beumer H, Hoepelman IM, Verhoef J (1991) Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Antimicrob Agents Chemother 35:858-868
82. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA (1988) Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158:831-847
83. Walker AP, Nichols RL, Wilson RF, Bivens BA, Trunkey DD, Smith JW, Condon RE, Edmiston CE Jr (1993) Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 217:115-121
84. Washington JA, Jones RN, Gerlach EH, Murray PR, Allen SD, Knapp CC (1993) Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime. Antimicrob Agents Chemother 37:1696-1700
85. Watanabe M, Haraguchi Y (1989) In vitro susceptibility of Bordetella parapertussis to various antimicrobial agents. Antimicrob Agents Chemother 33:968-969
86. Weber DJ, Saviteer SM, Rutala WA, Thomann CA (1988) In vitro susceptibility of Bacillus spp. to selected antimicrobial agents. Antimicrob Agents Chemother 32:642-645
87. Wilson SE (1993) Results of a randomized, multicenter trial of meropenem versus Clindamycin/tobramycin for the treatment of intra-abdominal infection. Clin Infect Dis 24 [Suppl 2]:197-206
88. Wittmann DH (1980) Chemotherapeutic principles in difficultto-treat infections in surgery. I. Peritonitis. Infection 8:323-329
89. Wittmann DH (1996) Duration of antibiotic treatment in surgical infections of the abdomen. Pharmacokinetic basis for short courses of antimicrobial therapy. Eur Surg 162 [Suppl 576]:19-23
90. Wittmann DH, Schassan H-H (1983) Penetration of eight betalactam antibiotics into peritoneal fluid. Arch Surg 112:205-212
91. Wittmann DH, Schein M (1996) Let us shorten antibiotic prophylaxis and therapy in surgery. Am J Surg 172:26S-32S
92. Wittmann DH, Schassan H-H, Freitag V (1980) Correlation of pharmacokinetic bacteriological findings with clinical results of antimicrobial therapy for peritonitis. In: Wiedemann B (ed) Die Resistenz gegenüber Beta-Lactam-Antibiotika. Paul-Erlich-Geselschaft für Chemotherapie, Bonn, pp 243-251
93. Wittmann DH, Kellinghusen C, Welter J, Freitag V (1983) Intraabdominelle Infektionen: Ergebnisse einer kontrollierten Therapiestudie. Akt Chir 18:229-253
94. Wittmann DH, Bergstein JM, Frantzides CT (1991) Calculated empiric antibiotic treatment of acute surgical infections. Infection 19:S345-S350
95. Wittmann DH, Walker A, Condon RE (1994) Peritonitis, intra-abdominal infection and intra-abdominal abscess Peritonitis and intraabdominal infection. In: Schwartz S et al (eds) Textbook of surgery principles of surgery. McGraw-Hill, New York, pp 1449-1483
96. Wittmann DH, Schein M, Condon RE (1996) Management of secondary peritonitis. Ann Surg 224:10-18